A Systematic Review of the Association of Neuregulin 4, a Brown Fat–Enriched Secreted Factor, With Obesity and Related Metabolic Disturbances Publisher Pubmed



Tutunchi H^{1, 2} ; Ostadrahimi A² ; Hosseinzadehattar MJ³ ; Miryan M¹ ; Mobasseri M⁴ ; Ebrahimimameghani M⁵ Show Affiliations
Source: Obesity Reviews Published:2020

Abstract

Neuregulin 4 (Nrg4), a novel brown fat–enriched hormone, plays a key role in the modulation of glucose and lipid metabolism and energy balance. Recent data have demonstrated that the expression of Nrg4 is substantially down-regulated in mouse and human obesity, making its regulatory aspect intriguing. Because of the close relationship between Nrg4, obesity, and associated metabolic diseases, this systematic review aimed to assess the association of Nrg4 with obesity and related metabolic disturbances, emphasizing its possible mechanisms of action in these disorders. We searched PubMed/Medline, ScienceDirect, Scopus, EMBASE, ProQuest, and Google Scholar up until June 2019. The evidence reviewed here indicates that Nrg4 may contribute to the prevention of obesity and related metabolic complications by elevating brown adipose tissue activity, increasing the expression of thermogenic markers, decreasing the expression of lipogenic/adipogenic genes, exacerbating white adipose tissue browning, increasing the number of brite/beige adipocytes, promoting hepatic fat oxidation and ketogenesis, inducing neurite outgrowth, enhancing blood vessels in adipose tissue, increasing the circulatory levels of healthy adipokines, and improving glucose homeostasis. Thus, Nrg4 appears to be a novel therapeutic strategy for the treatment of obesity and associated metabolic complications. However, prospective cohort studies are warranted to confirm these outcomes. © 2019 World Obesity Federation